Population exposure-safety and exposure-efficacy analyses for rucaparib in patients (pts) with recurrent ovarian carcinoma (rOC) from Study 10 and ARIEL2
Year: 2020
Type: article
Source: Gynecologic Oncology
Authors: G.E. Konecny, A.M. Oza, A.V. Tinker, A. Oaknin, R. Shapira-Frommer, I. Ray-Coquard, C. Aghajanian, R.L. Coleman, D.M. O'Malley, A. Leary, L.M. Chen, D. Provencher, L. Ma, J.D. Brenton, C.M. Castro, M. Green, A.D. Simmons, J. Beltman, T. Harding, S. Goble, L. Maloney, R. Kristeleit, I.A. McNeish, E.M. Swisher, J.J. Xiao
Institutions: University of California, Los Angeles, University Health Network, Princess Margaret Cancer Centre, BC Cancer Agency, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Sheba Medical Center, Centre Léon Bérard, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Inserm, Institut Gustave Roussy, University of California, San Francisco, Centre Hospitalier de l’Université de Montréal, Institut du cancer de Montréal, Université de Montréal, Rocky Mountain Cancer Centers, University of Cambridge, Harvard University, Massachusetts General Hospital, Certara (United States), Clovis Oncology (United States), University College London, Imperial College London, University of Washington
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3157715657